A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects

Lemtrada can provide a ray of hope for those with advances Relapse Recurring Multiple Sclerosis

Tuesday, June 11, 2019 - Lemtrada, an anti-seizure multiple sclerosis drug, is so powerful and potentially toxic that even the manufacturer has had to admit that it should be used only as a last resort and only if all other drugs have failed. As a result of its strength, Lemtrada also carries certain features that make taking the drug advisable for some.

According to the Multiple Sclerosis experts at Multiple Sclerosis News Today, "A five-year study demonstrated that Sanofi-Genzyme' Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease." Approximately 90% of the patients in the study were relapse-free for the following 3 years and 60% made it five years, a remarkable success." The infusion reactions of patients in the study were limited to headaches, slight fever and rashes according to the report. Six patients, or around 3 in every 1000, developed cancer. The study also indicated that some patients only needed to get the treatment in two phases. Lemtrada infusions are given in five consecutive days. One year later only three are usually required. Lemtrada lawyers helping families and persons that suffered from Lemtrada drug side effects and offer a free consultation before filing a lawsuit claim.

Interestingly, patients in the study were eager to share their experiences with taking Lemtrada. One woman reported a severe adverse reaction as her condition going from relatively stable to now requiring a wheelchair "I got progressively worse after treatment. I was stable, walking unassisted for 6 years after diagnosis, had Lemtrada, and in a year went from a cane to a walker. Now I'm in need of a chair. Everybody is different but I regret having this treatment!" Another MS patient was numb from the ribcage down and required a walker before using Lemtrada. After taking the drug she reported restoration of her sensations as well as walking unassisted. "Eternally grateful for Lemtrada!"

Doctors that specialize in RRMS are encouraged to have another weapon to use to help their patients fight the deadly and debilitating disease. One such doctor, Dr. Charles Asta, MD, a board-certified neurologist practicing in Teaneck, NJ, "provides clinical care and hope to those who have the potentially debilitating disease" according to North Jersey.com. The Dr. cites the drug's successful studies as well as the elimination of the need for additional medication for those taking Lemtrada. According to the website, Dr. Asta said: "it is remarkable that so many recipients of Lemtrada are not having relapses."

Before everyone rushes out to get Lemtrada, patients should be aware of the consequences of taking the drug which includes having a stroke and becoming paralyzed and also sudden death from having a heart attack. According to the drug's website Lemtrada.com, the drug should be considered only as a last resort because of the seriousness of its adverse safety profile. "LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. LEMTRADA causes serious and life-threatening infusion reactions, and serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of LEMTRADA administration." Read more about the risks of taking Lemtrada at https://www.lemtradahcp.com/safety-information#isi

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
• MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
• Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
• Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
• Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
• People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
• Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
• Lemtrada Patients Have May Have Safer Options | 12/8/2020
• Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
• Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
• Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
• Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
• Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
• Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
• Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
• Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
• Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
• Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
• Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
• RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
• New Information About COVID19 and Taking Lemtrada | 7/16/2020
• The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
• Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
• A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
• Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
• Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
• RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
• Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
• Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
• Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
• Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
• Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
• Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
• Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
• Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
• Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
• Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
• Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
• Lemtrada Fears May Be Overdone | 1/30/2020
• Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
• One Last Lemtrada Warning for 2019 | 1/2/2020
• RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
• Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
• Lemtrada Side Effect Awareness Requirements | 12/11/2019
• Lemtrada is serious medication for a serious condition | 11/21/2019
• More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
• RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
• Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
• Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
• Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
• Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
• RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
• Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
• Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
• Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
• Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
• Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
• Lemtrada Patients Report Promising Results | 8/1/2019
• The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
• What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
• Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
• Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
• Treating Multiple Sclerosis From Many Angles | 6/21/2019
• Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
• A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
• Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
• The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
• Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
• The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
• The Pros and Cons of Lemtrada Therapy | 4/19/2019
• Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
• Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
• MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
• Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
• Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
• Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.